Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer
Data up to Jan 2025
Total Citations Per Year
Abstract
References (15)
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
2000 • 15,583 citations
Anticancer Agents from Natural Products
2005 • 632 citations
In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B.
2001 • 480 citations
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
2005 • 472 citations
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data
1991 • 363 citations
Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389
2004 • 261 citations
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
2009 • 243 citations
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
2008 • 201 citations
Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin a, dolastatins 10 and 15 and halichondrin B
1992 • 186 citations
A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
2009 • 144 citations
Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
2009 • 138 citations
A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial
2005 • 75 citations
Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro
2007 • 46 citations
Discovery of E7389, a Fully Synthetic Macrocyclic Ketone Analog of Halichondrin B
2005 • 36 citations
Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy
2008 • 21 citations
Cited By (0)
No citing papers found in database